The stock is approaching a binary catalyst with prula-cel topline data expected within weeks. Traders should position for elevated volatility around the September 2026 data release, as the company's $81M market cap makes it highly sensitive to clinical outcomes. The ADI-212 IND clearance and in vivo CAR-T platform update are longer-term pipeline events that add optionality but do not change the near-term risk/reward.
Price Chart
Executive Summary
Adicet Bio announced completion of the last patient visit for the planned Phase 1 analysis of prula-cel in SLE with or without lupus nephritis, with topline data expected in September 2026. The company also disclosed FDA clearance of an IND for ADI-212 in mCRPC and plans to initiate a Phase 1 study in Q4 2026. This is a pipeline update with no financial data, and the stock's historical reaction to similar neutral filings has been mixed but includes large positive moves, suggesting binary event risk around the upcoming data readout.
Key Facts
- Completed last patient visit for planned Phase 1 analysis of prula-cel in SLE with or without LN; topline data expected September 2026.
- Planned analysis includes data from 22 SLE patients with or without LN with a minimum of 6 months follow-up, including 13 patients with at least 12 months follow-up.
- FDA cleared IND for ADI-212 in mCRPC; Phase 1 study expected to initiate in Q4 2026.
- First in vivo CAR-T candidate expected to enter clinical development in 2H 2027.
- Clinical update for prula-cel in systemic sclerosis expected in Q4 2026.
Financial Impact
No financial data provided in the filing. The company is a clinical-stage biotech with no approved products or reported revenue.
Risk Factors
- Prula-cel topline data may fail to meet efficacy or safety expectations, leading to significant downside.
- The company has no approved products or revenue, creating financing risk if clinical milestones are delayed or negative.
- Early-stage pipeline (ADI-212, in vivo CAR-T) has not yet generated clinical data, adding execution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001720580-26-000054 |
| Document: acet-ex99_1.htm | 0001720580-26-000054 |
| Document: 0001720580-26-000054-index-headers.html | 0001720580-26-000054 |
| Document: 0001720580-26-000054-index.html | 0001720580-26-000054 |
| Document: 0001720580-26-000054.txt | 0001720580-26-000054 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | SC 13G | $4.03 | awaiting T+20 | — | $3.94 (−2.22%) |
Sep 28, 2026 29d ago | 8-K | $6.35 $3.94 | ▼ −37.95% | ▼ −37.92% | $3.94 (−37.95%) |
Sep 1, 2026 8w ago | 8-K | $9.26 $7.12 | ▼ −23.11% | ▼ −24.29% | $3.94 (−57.45%) |
May 20, 2026 22w ago | 10-K/A | $7.89 $8.23 | ▲ +4.31% | ▲ +3.98% | $3.94 (−50.06%) |
May 13, 2026 23w ago | 8-K | $8.41 $8.05 | ▼ −4.28% | ▼ −3.42% | $3.94 (−53.15%) |
Apr 8, 2026 28w ago | 144 | $6.86 $8.55 | ▲ +24.64% | ▲ +17.07% | $3.94 (−42.57%) |
Apr 7, 2026 28w ago | 144 | $6.55 $8.51 | ▲ +29.92% | ▲ +21.38% | $3.94 (−39.85%) |
Mar 24, 2026 31w ago | EFFECT | $6.69 $8.31 | ▲ +24.22% | ▲ +15.31% | $3.94 (−41.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers